芦可替尼乳膏(Opzelura)治疗特应性皮炎效果好吗？

The effect of ruxolitinib cream (Opzelura) in the treatment of atopic dermatitis

Non-immunocompromised patients with mild to moderate atopic dermatitis (AD) can be treated with ruxolitinib cream (Opzelura). The effect is remarkable and it has been approved by the US FDA. In two phase 3 clinical trials, compared with placebo, more patients in the ruxolitinib group achieved an improvement of more than 50% in systemic vitiligo area score indicators. More than 51% of patients in the ruxolitinib group had at least a 50% improvement in facial vitiligo symptoms, and more than 15% of patients had a more than 90% improvement in facial symptoms. At week 24, 29.9% of patients treated with ruxolitinib cream (Opzelura) achieved at least a 75% improvement in facial vitiligo symptoms.

How safe is ruxolitinib cream (Opzelura) for treating atopic dermatitis?

Common side effects of ruxolitinib cream (Opzelura) are runny nose, tonsillitis, ear infection, bronchitis, hives, increased eosinophil (a type of white blood cell) count, diarrhea, folliculitis, and pain or swelling of the nose or throat (nasopharyngitis). In addition, it should be noted that ruxolitinib cream (Opzelura) also carries a black box warning, reminding patients that using JAK inhibitors to treat inflammation may cause thrombosis, cardiovascular events, malignant tumors, mortality, and serious infections. Patients should pay attention to their physical reactions during medication. If they are intolerant, contact their doctor promptly for symptomatic treatment.

At the 24th World Congress of Dermatology (WCD) held in Milan, Italy, in June 2019, Incyte, the company that developed ruxolitinib cream (Opzelura), announced a study. The main side effect of ruxolitinib cream (Opzelura) was an increase in acne in 10% to 15% of patients, while other side effects were not obvious. All doses of ruxolitinib cream were well tolerated.

Ruxolitinib cream can selectively inhibit JAK1/JAK2. JAKs belongs to the cytoplasmic tyrosine kinase family and is a Janus kinase (JAK) inhibitor. Vitiligo cannot be cured and is difficult to control. Ruxolitinib cream is a promising choice for patients with vitiligo. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: